.png)
MeMed
FDA-cleared host-immune-response test (bacterial vs viral) at the point of need
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
MeMed is positioned as a high-credibility host-response diagnostics company advancing from product validation into commercialization, with clear emphasis on FDA-cleared and CE-marked infectious disease assays, AI-enabled diagnostics, and acute-care data infrastructure.[1][7][9][19] Its trajectory suggests dual-use relevance through antibiotic stewardship, sepsis-adjacent triage, and defense-linked funding history, while continuing to expand evidence generation and platform breadth.[7][13][15]
Efficiency Ratio
The company appears to convert a relatively lean operating base into substantial regulatory, scientific, and fundraising outcomes, indicating strong output efficiency for its scale.[10][12][15]
Evidence Signals
MeMed BV is described as the first FDA-cleared host-immune response assay for distinguishing bacterial from viral infections in 15 minutes.
MeMed raised $93 million in a private financing round to help commercialize its tools.
The company has raised $163 million across 10 funding rounds, according to a company profile source.
MeMed received a $2 million grant from Israel’s Innovation Authority to establish an acute-care diagnostics and proteomics biobank.
MeMed was awarded a $4.1 million grant by the U.S. Department of Defense to support development of its automated medical diagnosis technology.
MeMed received CE Mark in Europe for MeMed BV and MeMed Key point-of-need platform.
LinkedIn lists the company’s headquarters in Haifa, Israel and a U.S. office in Andover, Massachusetts, indicating a bi-regional footprint.
- About
- Israeli med-tech / bio-convergence company (HQ Haifa, Israel; US operations in Andover/Boston, MA), founded around 2009 by Eran Eden (CEO) and Dr. Kfir Oved (both Technion). MeMed decodes the body's host immune response into rapid diagnostic scores. Its MeMed BV® is the first FDA-cleared host-response test to distinguish bacterial from viral infection in ~15 minutes (measuring TRAIL, IP-10, CRP) on the point-of-need MeMed Key® analyzer; the pipeline adds MeMed Severity™ (FDA Breakthrough Device Designation for predicting deterioration/sepsis) and the fingerstick MeMed BV Flex™ (Breakthrough Device Designation, 2026). Raised >$200M (incl. a $93M round) with direct support from the US Department of Defense and the EU Commission. Point-of-need infection/sepsis triage and antimicrobial stewardship make it a strong dual-use combat-casualty-care fit.
- Tags
- #hostresponse #diagnostics #sepsis #bacterialviral #pointofcare #ivd #ml #fda #dod #amr #dualuse